Comparative Pharmacology
Head-to-head clinical analysis: SILDENAFIL CITRATE versus YESAFILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SILDENAFIL CITRATE versus YESAFILI.
SILDENAFIL CITRATE vs YESAFILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sildenafil citrate inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cGMP levels and enhancing nitric oxide-mediated smooth muscle relaxation, leading to penile erection. It also inhibits PDE5 in pulmonary vasculature, causing vasodilation and reducing pulmonary artery pressure.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing a conformational change leading to receptor degradation and inhibition of estrogen-dependent tumor growth.
50 mg orally as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability; maximum dosing frequency once per day.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 3-5 hours; clinical effect duration shorter due to distribution.
Terminal elimination half-life of 3–5 hours in healthy adults; prolonged in hepatic impairment (up to 8–10 hours), requiring dose adjustment.
Approximately 80% fecal, 13% renal as metabolites; <1% unchanged in urine.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 2% of the dose, with biliary/fecal elimination as the major route.
Category A/B
Category C
PDE5 Inhibitor
PDE5 Inhibitor